


L1

STR



G1 Ak,Cy

Structure attributes must be viewed using STN Express query preparation.

```
=> s 11
SAMPLE SEARCH INITIATED 16:13:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 27 TO ITERATE
```

```
100.0% PROCESSED 27 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 229 TO 851
PROJECTED ANSWERS: 4 TO 200
```

L2 4 SEA SSS SAM L1

```
=> s 11 sss full
FULL SEARCH INITIATED 16:13:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 335 TO ITERATE
```

```
100.0% PROCESSED 335 ITERATIONS 81 ANSWERS
SEARCH TIME: 00.00.01
```

L3 81 SEA SSS FUL L1

```
=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
                           ENTRY SESSION
FULL ESTIMATED COST      178.36 178.57
```

```
FILE 'CAPLUS' ENTERED AT 16:13:55 ON 19 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 May 2008 VOL 148 ISS 21
FILE LAST UPDATED: 18 May 2008 (20080518/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 13

L4 9 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007144056 CAPLUS
 DOCUMENT NUMBER: 146:229363
 TITLE: Preparation of oxazine derivatives as Ep4 receptor agonists and antiglaucoma agents
 INVENTOR(S): Colucci, John; Han, Yongxin; Farand, Julie A.
 PATENT ASSIGNEE(S): Merck Frost Canada Ltd., Can.
 SOURCE: PCT Int. Appl., 54pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007014462	A1	20070208	WO 2006-CA1254	20060728
WI, AE, BG, AL, AM, AT, NL, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, L1, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BE, BJ, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006275263	A1	20070208	AU 2006-275263	20060728
CA 2616608	A1	20070208	CA 2006-2616608	20060728
EP 1912957	A1	20080423	EP 2006-761199	20060728
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, L1, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.: US 2005-705120P			P 20050803	
		WO 2006-CA1254	W 20060728	

OTHER SOURCE(S): MARPAT 146:229363
 GI

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 924623-13-2P 924623-14-3P 924623-15-4P
 924623-16-5P 924623-17-6P 924623-18-7P
 924623-19-8P 924628-52-4P 924628-53-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of oxazine derivs. as Ep4 receptor agonists antiglaucoma agents)

RN 924622-95-7 CAPLUS

CN Benzoic acid, 4-[2-[(4S)-4-[(3R)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxybutyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]ethyl]- (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 924622-97-9 CAPLUS

CN Benzoic acid, 4-[2-[(4S)-4-[(3R)-4,4-difluoro-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.





RN 924622-99-1 CAPLUS

CN Benzoic acid, 4-[2-[(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-butene-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-

Habte

05/19/2008

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors I, wherein R represents $(CH_2)_xCOOR_3$, $(CH_2)_xC_3-10$ cycloalkyl, $-(CH_2)_nC_3-10$ heterocyclyl, $(CH_2)_nC_5-10$ aryl, said cycloalkyl, heterocyclyl, and aryl substituted with R2; provided that when


R is $-(CH_2)_nC_3-10$ heterocyclyl it does not represent thiienyl; R1 independently represents hydrogen, C1-6-alkyl, halogen, CF3, aryl, said aryl optionally substituted with 1-3 groups of halogen, Cl-alkyl, CF3, or N(R4)2; R2 represents COOR3 or a carboxylic acid isostere; R3 and R4 independently represent H, or Cl-6-alkyl; n represents 0-3; x is 2-5; their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compds.

of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts. Thus, oxazine II was prepared and tested in rats as EP4 receptor agonist in osteoblastic cell lines and in bone tissue. Effects of an EP4 agonist on intraocular pressure in rabbits and monkeys, are reported. Title compds. showed improved ocular tolerability in animal species such as rabbits and cynomolgus monkeys. The activity range of the compds. of this invention for bone use is between 0.01 and 100,000 nM. Stable expression of prostanoid receptors in the human embryonic kidney (HEK) 293 (EBNA) cell line is reported.

IT 924622-95-7P 924622-97-9P 924622-99-1P
 924623-02-9P 924623-03-0P 924623-05-2P
 924623-06-3P 924623-07-4P 924623-08-5P
 924623-09-6P 924623-11-0P 924623-12-1P

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 924623-02-9 CAPLUS

CN Benzoic acid, 4-[2-[(4S)-4-[(3R)-4-(3,5-dimethylphenyl)-4,4-difluoro-3-hydroxybutyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 924623-03-0 CAPLUS

CN Benzoic acid, 4-[2-[(4S)-4-[(3R)-4,4-difluoro-3-hydroxy-4-phenylbutyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 924623-05-2 CAPLUS
CN Benzoic acid,
4-[2-[(4R)-4-[(1E,3R)-4-(3,5-dichlorophenyl)-4,4-difluoro-3-hydroxy-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 924623-06-3 CAPLUS
CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(1E,3R)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxy-1-buten-1-yl]dihydro-2-oxo-, (4R)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 924623-07-4 CAPLUS
CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[4-(3-bromophenyl)-4,4-difluoro-3-hydroxybutyl]dihydro-2-oxo-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 924623-08-5 CAPLUS
CN 2H-1,3-Oxazine-3(4H)-heptanoic acid,
4-[(1E,3R)-4-(1'-biphenyl)-3-yl-4,4-difluoro-3-hydroxy-1-buten-1-yl]dihydro-2-oxo-, (4R)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 924623-09-6 CAPLUS
CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-(2'-methyl[1,1'biphenyl]-3-yl)-1-buten-1-yl]dihydro-2-oxo-, (4R)- (CA INDEX NAME)


L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.



RN 924623-11-0 CAPLUS
CN Benzoic acid, 4-[3-[(4S)-4-[(3R)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxybutyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 924623-12-1 CAPLUS
CN Benzoic acid, 4-[3-[(4R)-4-[(1E,3R)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxy-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 924623-13-2 CAPLUS
CN 2-Pyridinecarboxylic acid, 6-[3-[(4R)-4-[(1E,3R)-4-(3,5-dichlorophenyl)-4,4-difluoro-3-hydroxy-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 924623-14-3 CAPLUS
CN 2-Pyridinecarboxylic acid, 6-[3-[(4R)-4-[(1E,3R)-4-(3,5-dichlorophenyl)-4,4-difluoro-3-hydroxy-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 924623-15-4 CAPLUS
CN 5-Thiazolecarboxylic acid, 2-[3-[(4R)-4-[(1E,3R)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxy-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 924623-16-5 CAPLUS
CN 5-Thiazolecarboxylic acid, 2-[3-[(4R)-4-[(1E,3R)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxy-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 924623-17-6 CAPLUS
CN Benzoic acid, 3-[3-[(4R)-4-[(1E,3R)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxy-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 924623-18-7 CAPLUS
CN Benzoic acid, 3-[3-[(4S)-4-[(3R)-4-(3-bromophenyl)-4,4-difluorobutyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 924623-19-8 CAPLUS
CN 3-Isoxazolcarboxylic acid, 5-[3-[(4R)-4-[(1E,3R)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxy-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 924623-52-4 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[2-[(4R)-4-[(1E,3R)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxy-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 924623-53-5 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[2-[(4S)-4-[(3R)-4-(3-bromophenyl)-4,4-difluorobutyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 924622-92-4P 924622-93-5P 924622-94-6P
924622-96-8P 924622-98-0P 924623-00-7P
924623-01-8P 924623-04-1P 924623-10-9P
924623-27-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxazine derivs. as Ep4 receptor agonists antiglaucoma agents)


RN 924622-92-4 CAPLUS
CN Benzoic acid, 4-[2-[(4R)-4-[(1E,3R)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxy-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]ethyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 924622-93-5 CAPLUS
CN Benzoic acid, 4-[2-[(4R)-4-[(1E,3R)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxy-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 924622-94-6 CAPLUS
CN Benzoic acid, 4-[2-[(4S)-4-[(3R)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxybutyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]ethyl], 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 924622-96-8 CAPLUS
CN Benzoic acid, 4-[2-[(4S)-4-[(3R)-4,4-difluoro-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]ethyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 924622-98-0 CAPLUS
CN Benzoic acid, 4-[2-[(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-[3-(trifluoromethyl)phenyl]1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]ethyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 924623-00-7 CAPLUS
CN Benzoic acid, 4-[2-[(4R)-4-[(1E,3R)-4-(3,5-dimethylphenyl)-4,4-difluoro-3-hydroxy-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]ethyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 924623-01-8 CAPLUS
CN Benzoic acid, 4-[2-[(4R)-4-[(1E,3R)-4-(3,5-dimethylphenyl)-4,4-difluoro-3-hydroxy-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 924623-04-1 CAPLUS
CN Benzoic acid, 4-[2-[(4R)-4-[(1E,3R)-4-(3,5-dichlorophenyl)-4,4-difluoro-3-hydroxy-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]ethyl]-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 924623-10-9 CAPLUS
CN Benzoic acid, 4-[3-[(4R)-4-[(1E,3R)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxy-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 924623-27-8 CAPLUS
 CN Benzoic acid, 4-[2-[(4R)-4-[(1E)-4-(3-bromophenyl)-4,4-difluoro-3-oxo-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]ethyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:143969 CAPLUS
 DOCUMENT NUMBER: 146:229362
 TITLE: Preparation of oxazine derivatives as EP4 receptor agonists and antiglaucoma agents
 INVENTOR(S): Colucci, John; Han, Yongxin; Farand, Julie A.
 PATENT ASSIGNEE(S): Merck Frost Canada Ltd., Can.
 SOURCE: PCT Int. Appl., 47pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007014454	A1	20070208	WO 2006-CA1243	20060728
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LS, LT, LU, LV, LY, MA, MD, MG, MK, MW, MW, MN, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, US, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BP, BJ, CP, CO, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, KG, KZ, MD, RU, TJ, TM				
AU 2006275270	A1	20070208	AU 2006-275270	20060728
CA 2616604	A1	20070208	CA 2006-2616604	20060728
EP 1912977	A1	20080423	EP 2006-761196	20060728
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.: US 2005-705124P				P 20050803

WO 2006-CA1243 W 20060728

OTHER SOURCE(S): MARPAT 146:229362
 GI

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




AB This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors I, wherein R1 independently represents hydrogen, C1-6 alkyl, halogen, CF3, aryl, said aryl optionally substituted with 1 to 3 groups of halogen, C1-6 alkyl, CF3, substituted amine; R2 represents H, or halogen; R3 represents COOR or carboxylic acid isostere; n represents 0-3; their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compds. of this invention for mediating the bone remodeling and remodeling processes of the osteoblasts and osteoclasts. Thus, oxazine II was prepared and tested in rats as EP4 receptor agonist in osteoblastic cell lines and in bone tissue. Effects of an EP4 agonist on intraocular pressure in rabbits and monkeys, are reported. Title compds. showed improved ocular tolerability in animal species such as rabbits and cynomolgus monkeys.

IT 924300-94-7P 924300-95-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of oxazine derivs. as EP4 receptor agonists and antiglaucoma agents)

RN 924300-94-7 CAPLUS
 CN 2-Thiophencarboxylic acid, 5-[3-[(4R)-4-[(1E,3R)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxy-1-butyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-


L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 yl]propyl]-, 1-methylethyl ester (CA INDEX NAME) (Continued)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 924300-95-8 CAPLUS
 CN 2-Thiophencarboxylic acid, 5-[3-[(4R)-4-[(1E,3R)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxy-1-butyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




IT 924300-96-9P 924300-98-1P 924301-00-8P
 924301-03-1P 924301-05-3P 924301-07-5P
 924301-08-6P 924301-09-7P 924301-11-1P
 924301-12-2P 924301-13-3P 924301-15-5P
 924301-37-1P 924301-38-2P 924301-39-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of oxazine derivs. as EP4 receptor agonists and antiglaucoma agents)

RN 924300-96-9 CAPLUS
 CN 2-Thiophencarboxylic acid, 5-[3-[(4S)-4-[(3R)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxybutyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (CA


L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
INDEX NAME)

Absolute stereochemistry.



RN 924300-98-1 CAPLUS
CN 2-Thiophene carboxylic acid, 5-[3-[(4R)-4-[(1E,3R)-4-(3,5-dichlorophenyl)-4,4-difluoro-3-hydroxy-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 924301-00-8 CAPLUS
CN 2-Thiophene carboxylic acid, 5-[3-[(4S)-4-[(3R)-4-(3,5-dichlorophenyl)-4,4-difluoro-3-hydroxybutyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 924301-03-1 CAPLUS
CN 2-Thiophene carboxylic acid, 5-[3-[(4S)-4-[(3R)-4-(3,5-dimethylphenyl)-4,4-difluoro-3-hydroxybutyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 924301-05-3 CAPLUS
CN 2-Thiophene carboxylic acid, 5-[3-[(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-butyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 924301-07-5 CAPLUS
CN 2-Thiophene carboxylic acid, 5-[3-[(4S)-4-[(3R)-4,4-difluoro-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 924301-09-7 CAPLUS
CN 2-Thiophene carboxylic acid, 5-[3-[(4S)-4-[(3R)-4,4-difluoro-3-hydroxy-4-[1-methylethyl]phenyl]butyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 924301-08-6 CAPLUS
CN 2-Thiophene carboxylic acid, 5-[3-[(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-[3-(1-methylethyl)phenyl]-1-butyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 924301-11-1 CAPLUS
CN 2-Thiophene carboxylic acid, 4-bromo-5-[3-[(4R)-4-[(1E,3R)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxy-1-butyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 924301-12-2 CAPLUS
 CN 2-Thiophene carboxylic acid, 5-[3-[(4R)-4-[(1E,3R)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxy-1-butyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 924301-13-3 CAPLUS
 CN 2-Thiophene carboxylic acid, 5-[3-[(4S)-4-[(3R)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxybutyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-3-fluoro- (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 924301-15-5 CAPLUS
 CN 2-Thiophene carboxylic acid, 5-[3-[(4R)-4-[(1E,3R)-4-(3-bromo-5-iodophenyl)-4,4-difluoro-3-hydroxy-1-butyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 924301-37-1 CAPLUS
 CN 2-Thiophene carboxylic acid, 5-[3-[(4R)-4-[(1E)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxy-1-butyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 924301-38-2 CAPLUS
 CN 2-Thiophene carboxylic acid, 5-[3-[(4S)-4-[(3R)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxybutyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 924301-39-3 CAPLUS
 CN 2-Thiophene carboxylic acid, 5-[3-[(4S)-4-[(3R)-4-(3,5-dimethylphenyl)-4,4-difluoro-3-hydroxybutyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 768400-29-9P 924300-97-0P 924300-99-2P
 924301-01-9P 924301-02-0P 924301-04-2P
 924301-06-4P 924301-10-0P 924301-21-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of oxazine derivs. as EP4 receptor agonists and antiglaucoma agents)

RN 768400-29-9 CAPLUS
 CN 2-Thiophene carboxylic acid, 5-[3-[(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-4-[(1E)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxy-1-butyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 924300-97-0 CAPLUS
 CN 2-Thiophene carboxylic acid, 5-[3-[(4R)-4-[(1E,3R)-4-(3,5-dichlorophenyl)-4,4-difluoro-3-hydroxy-1-butyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 924300-99-2 CAPLUS
CN 2-Thiophencarboxylic acid, 5-[3-[(4S)-4-[(3R)-4-(3,5-dichlorophenyl)-4,4-difluoro-3-hydroxybutyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 924301-02-0 CAPLUS
CN 2-Thiophencarboxylic acid, 5-[3-[(4R)-4-[(1E,3R)-4-(3,5-dimethylphenyl)-4,4-difluoro-3-hydroxy-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 924301-01-9 CAPLUS
CN 2-Thiophencarboxylic acid, 5-[3-[(4R)-4-[(1E,3R)-4-(3,5-dimethylphenyl)-4,4-difluoro-3-hydroxy-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 924301-04-2 CAPLUS
CN 2-Thiophencarboxylic acid, 5-[3-[(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 924301-06-4 CAPLUS
CN 2-Thiophencarboxylic acid, 5-[3-[(4S)-4-[(3R)-4,4-difluoro-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 924301-21-3 CAPLUS
CN 2-Thiophencarboxylic acid, 5-[3-[(4R)-4-[(1E)-4-(3-bromophenyl)-4,4-difluoro-3-oxo-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 924301-10-0 CAPLUS
CN 2-Thiophencarboxylic acid, 4-bromo-5-[3-[(4R)-4-[(1E,3R)-4-(3-bromophenyl)-4,4-difluoro-3-hydroxy-1-buten-1-yl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:1136535 CAPLUS
 DOCUMENT NUMBER: 146:100991
 TITLE: Efficient Asymmetric Synthesis of Quaternary (E)-Vinylglycines by Deconjugative Alkylation of Dehydroamino Acids
 AUTHOR(S): Jones, Matthew C.; Marsden, Stephen P.; Subtil, Dulce M. Munoz
 CORPORATE SOURCE: School of Chemistry, University of Leeds, Leeds, LS2 9JT, UK
 SOURCE: Organic Letters (2006), 8(24), 5509-5512
 CODEN: ORLEF7; ISSN: 1523-7060
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 146:100991
 GI



AB A two-step protocol for the asym. synthesis of protected quaternary (E)-vinylglycines from simple aldehydes is reported. The key step is a regiocontrolled deconjugative asym. alkylation of dehydroamino acids, such that the target compds. are produced as single geometric isomers with high diastereoselectivity. For example, dehydroamino acid I (R1 = C8H17, Ph, CH2Ph) are alkylated in presence of LDA, LiCl in THF to give vinylglycines II (R2 = Me, Et, CH2Ph, CH2CH2CH2, CH2OCH2Ph, CH2CO2Bu-t) in yields $\geq 33\%$ with 92-96% diastereomeric excess. II can be converted to protected quaternary β -amino alcs., oxazolidinones III, by chemoselective reduction.
 IT 917603-84-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (asym. synthesis of quaternary vinylglycines by deconjugative alkylation)

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 of dehydroamino acids)
 RN 917603-84-0 CAPLUS
 CN 2H-1,3-Oxazin-2-one, 4-(1E)-1-decen-1-yltetrahydro-4-(hydroxymethyl)-, (4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:116566 CAPLUS
 DOCUMENT NUMBER: 144:192030
 TITLE: Preparation of prostaglandin analogs as antiglaucoma agents
 INVENTOR(S): Old, David W.; Dinh, Danny T.
 PATENT ASSIGNEE(S): Allergan, Inc., USA
 SOURCE: PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006014207	A1	20060209	WO 2005-US19409	20050602
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005270230	A1	20060209	AU 2005-270230	20050602
CA 2571786	A1	20060209	CA 2005-2571786	20050602
EP 1771427	A1	20070411	EP 2005-761544	20050602
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20060276461	A1	20061207	US 2005-552083	20051004
PRIORITY APPLN. INFO.:			US 2004-584962P	P 20040702
			US 2004-600165P	P 20040809
			WO 2005-US19409	W 20050602

OTHER SOURCE(S): MARPAT 144:192030
 GI

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CHOH; E = alkyl, cycloalkyl, Ph, naphthyl) or a pharmaceutically acceptable salt or a produg thereof is disclosed herein. These compds. are useful for treating glaucoma or ocular hypertension.
 IT 875314-81-1P, derive
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of prostaglandin analogs as antiglaucoma agents)
 RN 875314-81-1 CAPLUS
 CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, dihydro-4-(3-hydroxy-4-phenylbutyl)-2-oxo- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT



AB Compds. of formula I [A = (CH2)6, cis-CH2CH=CH(CH2)3, CH2C.tpbond.C(CH2)3; Z = O, S, (substituted) NH; X = CO2H, (substituted) CONH2, etc.; J = CO,

Habte

05/19/2008

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:1106800 CAPLUS
 DOCUMENT NUMBER: 143:387049
 TITLE: Preparation of disubstituted piperidinones, oxazinanones, thiazinanones, and morpholinones as EP4 receptor agonist for treatment of ocular and bone disorders
 INVENTOR(S): Billot, Xavier; Colucci, John; Han, Yongxin; Wilson, Marie-claire; Young, Robert N.
 PATENT ASSIGNEE(S): Can.
 SOURCE: U.S. Pat. Appl. Publ., 30 pp., Division of U.S. Ser. No. 297,257.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050227969	A1	20051013	US 2005-146992	20050607
US 7238710	B2	20070703		
US 20040198701	A1	20041007	US 2004-797257	20040310
US 7053085	B2	20060530		
BR 2004008690	A	20060328	BR 2004-8690	20040326
IN 2005DNO3925	A	20070834	IN 2005-DN3925	20050902
IN 2005DNO3928	A	20070824	IN 2005-DN3928	20050902
MX 2005PA10189	A	20060222	MX 2005-PA10189	20050923
NO 2005004951	A	20051222	NO 2005-4951	20051025
PRIORITY APPLN. INFO.:			US 2003-457700P	P 20030326
			US 2004-797257	A3 20040310
			WO 2004-CA471	W 20040326

OTHER SOURCE(S): MARPAT 143:387049

AB This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compds. of this invention for mediating the bone

modeling and remodeling processes of the osteoblasts and osteoclasts. In particular, this invention relates to a series of 1,6-disubstituted piperidin-2-one, 3,4-disubstituted 1,3-oxazinan-2-one, 3,4-disubstituted 1,3-thiazinan-2-one, and 4,5-disubstituted morpholin-3-one deriva. The compds. of the invention are optionally formulated with other therapeutic agents known in treating eye disorders or in stimulating bone formation such as β -adrenergic blocking agents, carbonic anhydrase inhibitors, and bisphosphonates. Preparation schemes for the compds. of the invention are disclosed.

IT 768399-98-0


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 Preparation of disubstituted piperidinones, oxazinanones, thiazinanones, and morpholinones as EP4 receptor agonists for treatment of ocular and bone disorders

RN 768399-99-1 CAPLUS

CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-buten-1-yl]dihydro-2-oxo-, (4R)- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 768400-11-9 CAPLUS

CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-buten-1-yl]dihydro-2-oxo-, (4R)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 768400-14-2 CAPLUS

CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(3R)-4,4-difluoro-3-hydroxy-4-phenylbutyl]dihydro-2-oxo-, (4S)- (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 Preparation; RACT (Reactant or reagent); USES (Uses)
 (drug candidate; prepn. of disubstituted piperidinones, oxazinanones, thiazinanones, and morpholinones as EP4 receptor agonists for treatment of ocular and bone disorders)

RN 768399-98-0 CAPLUS

CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-buten-1-yl]dihydro-2-oxo-, 1-methylethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



IT 768399-99-1P 768400-11-9P, 7-[(4R)-4-((1E,3R)-4,4-difluoro-3-hydroxy-4-phenylbutyl-1-enyl)-2-oxo-1,3-oxazinan-3-yl]heptanoic acid 768400-14-2P, 7-[(4S)-4-((3R)-4,4-Difluoro-3-hydroxy-4-phenylbutyl-1-enyl)-2-oxo-1,3-oxazinan-3-yl]heptanoic acid 768400-18-6P, Isopropyl

7-[(4R)-4-((1E,3R)-4,4-difluoro-3-hydroxy-4-phenylbutyl-1-enyl)-2-oxo-1,3-oxazinan-3-yl]heptanoate 768400-21-1P, (4R)-4-((1E,3R)-4,4-difluoro-3-hydroxy-4-phenylbutyl-1-enyl)-3-[6-(2H-tetrazol-5-yl)hexyl]-1,3-oxazinan-2-one 768400-29-9P,

5-[(4R)-4-((1E,3R)-4,4-Difluoro-3-hydroxy-4-phenylbutyl-1-enyl)-2-oxo-1,3-oxazinan-3-yl]heptanoic acid 768400-32-4P, (4R)-4-((1E,3R)-4,4-Difluoro-3-hydroxy-4-phenylbutyl-1-enyl)-3-[3-(5-(2H-tetrazol-5-yl)hexyl)-1,3-oxazinan-2-one 768400-35-7P


(4S)-4-((1E,3R)-4,4-Difluoro-3-hydroxy-4-phenylbutyl-1-enyl)-3-[3-[5-(2H-tetrazol-5-yl)thien-2-yl]propyl]-1,3-oxazinan-2-one 768400-40-4P, Isopropyl

5-[(4R)-4-((1E,3R)-4,4-difluoro-3-hydroxy-4-phenylbutyl-1-enyl)-2-oxo-1,3-oxazinan-3-yl]propylthiophene-2-carboxylate

866465-52-3P, (SE)-7-[(4R)-4-((1E,3R)-4,4-Difluoro-3-hydroxy-4-phenylbutyl-1-enyl)-2-oxo-1,3-oxazinan-3-yl]hept-5-enoic acid 866465-55-6P, (SE)-7-[(4S)-4-((3R)-4,4-Difluoro-3-hydroxy-4-phenylbutyl-1-enyl)-2-oxo-1,3-oxazinan-3-yl]hept-5-enoic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 768400-18-6 CAPLUS

CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-buten-1-yl]dihydro-2-oxo-, 1-methylethyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 768400-21-1 CAPLUS


CN 2H-1,3-Oxazine-2-one, 4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-buten-1-yl]tetrahydro-3-[6-(2H-tetrazol-5-yl)hexyl]-, (4R)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 768400-29-9 CAPLUS
CN 2-Thiophene carboxylic acid,
5-[3-[(4R)-4-((1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butyl)dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 768400-32-4 CAPLUS
CN 2H-1,3-Oxazin-2-one,
4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butyl]tetrahydro-3-[3-[5-(2H-tetrazol-5-yl)-2-thienyl]propyl]-, (4R)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 768400-35-7 CAPLUS
CN 2H-1,3-Oxazin-2-one, 4-[(3R)-4,4-difluoro-3-hydroxy-4-phenylbutyl]tetrahydro-3-[3-[5-(2H-tetrazol-5-yl)-2-thienyl]propyl]-, (4S)- (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 768400-40-4 CAPLUS
CN 2-Thiophene carboxylic acid,
5-[3-[(4R)-4-((1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butyl)dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 866465-52-3 CAPLUS
CN 5-Heptenoic acid, 7-[(4R)-4-((1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butyl)dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]-, (5E)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 866465-55-6 CAPLUS
CN 5-Heptenoic acid, 7-[(4R)-4-((3S)-4,4-difluoro-3-hydroxy-4-phenylbutyl)dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]-, (5E)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



IT 768400-09-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of disubstituted piperidinones, oxazinanones, thiazinanones, and morpholinones as EP4 receptor agonists for treatment of ocular and bone disorders)
RN 768400-09-5 CAPLUS
CN 2H-1,3-Oxazine-3(4H)-heptanoic acid,
4-[(1E)-4,4-difluoro-3-oxo-4-phenyl-1-butyl]dihydro-2-oxo-, 1-methylethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:817887 CAPLUS
 DOCUMENT NUMBER: 141:314052
 TITLE: Preparation of prostaglandin analogs as EP4 receptor agonists for the treatment of glaucoma
 INVENTOR(S): Billot, Xavier; Colucci, John; Han, Yongxin; Wilson, Marie-Claire; Young, Robert N.
 PATENT ASSIGNEE(S): Merck Frost Canada & Co., Can.
 SOURCE: PCT Int. Appl., 69 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004085430	A1	20041007	WO 2004-CA470	20040326
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
FW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BI, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004224261	A1	20041007	AU 2004-224261	20040326
CA 2519938	A1	20041007	CA 2004-2519938	20040326
WO 2004085431	A1	20041007	WO 2004-CA471	20040326
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
FW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BI, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1613621	A1	20060111	EP 2004-723484	20040326
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HO, PL, SK				
BR 2004008690	A	20060328	BR 2004-8690	20040326
CN 1764659	A	20060426	CN 2004-80008186	20040326
JP 2006520758	T	20060914	JP 2006-504090	20040326
IN 2005DN03925	A	20070824	IN 2005-DN3925	20050902
IN 2005DN03928	A	20070824	IN 2005-DN3928	20050902
MX 2005PA10189	A	20060222	MX 2005-PA10189	20050923
NO 2005004951	A	20051222	NO 2005-4951	20051025
PRIORITY APFLN. INFO.:		US 2003-457700P	P	20030326

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 768399-99-1 CAPLUS
 768400-11-9P 768400-11-9P 768400-14-2P
 768400-16-4P 768400-18-6P 768400-21-1P
 768400-26-6P 768400-29-9P 768400-32-4P
 768400-35-7P 768400-37-9P 768400-40-4P
 768400-43-7P 768400-46-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of prostaglandin analogs as EP4 receptor agonists for the treatment of glaucoma)

RN 768399-99-1 CAPLUS
 CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butene-1-yl]dihydro-2-oxo-, (4R)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 768400-11-9 CAPLUS
 CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butene-1-yl]dihydro-2-oxo-, (4R)- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

Habte

05/19/2008

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued) (Continued)
 WO 2004-CA470 A 20040326

OTHER SOURCE(S): MARPAT 141:314052
 GI



II

AB Prostaglandin analogs of formula I [Q = alkylene, alkylarylene, alkylcycloalkylene, etc.; X, Y = CH2, O, (substituted) NH, S; U = H, alkyl, absent; W = OH, oxo; R1 = hydroxyalkyl, cyanoalkyl, carboxy, heterocyclylalkyl, etc.; R2 = alkyl, aryl, heteraryl, etc.; R3, R4 = H, halo, alkyl; R3R4 = alkylene, etc.; Z = triple bond, O, S, CH=CH, etc.; n = 0-4] are prepared as potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, and can be used in a formulation for the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compds. of this invention for mediating the


bone modeling and remodeling processes of the osteoblasts and osteoclasts. Thus, II was prepared in several steps from (R)-piperolic acid.

IT 768399-98-0P RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of prostaglandin analogs as EP4 receptor agonists for the treatment of glaucoma)

RN 768399-98-0 CAPLUS
 CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butene-1-yl]dihydro-2-oxo-, 1-methylethyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 768400-14-2 CAPLUS
 CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(3R)-4,4-difluoro-3-hydroxy-4-phenylbutyl]dihydro-2-oxo-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 768400-16-4 CAPLUS
 CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, dihydro-4-[(3R)-3-hydroxy-4-phenylbutyl]-2-oxo-, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768400-18-6 CAPLUS
 CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butene-1-yl]dihydro-2-oxo-, 1-methylethyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 768400-21-1 CAPLUS
CN 2H-1, 3-Oxazin-2-one,
4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]tetrahydro-3-[6-(2H-tetrazol-5-yl)hexyl]-, (4R)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 768400-26-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[3-[(4R)-dihydro-4-[(1E,3S)-3-hydroxy-4-phenyl-1-butenyl]-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 768400-29-9 CAPLUS
CN 2-Thiophenecarboxylic acid,
5-[3-[(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 768400-32-4 CAPLUS
CN 2H-1, 3-Oxazin-2-one,
4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]tetrahydro-3-[3-[(5-(2H-tetrazol-5-yl)-2-thienyl)propyl]-, (4R)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 768400-35-7 CAPLUS
CN 2H-1, 3-Oxazin-2-one, 4-[(3R)-4,4-difluoro-3-hydroxy-4-phenylbutyl]tetrahydro-3-[3-[(5-(2H-tetrazol-5-yl)-2-thienyl)propyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 768400-37-9 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[3-[(4R)-dihydro-4-[(1E,3S)-3-hydroxy-4-phenyl-1-butenyl]-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-, 1-methylethyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 768400-40-4 CAPLUS
CN 2-Thiophenecarboxylic acid,
5-[3-[(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-, 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 768400-43-7 CAPLUS
CN 5-Heptenoic acid, 7-[(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]-, (5E)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 768400-46-0 CAPLUS
CN 5-Heptenoic acid, 7-[(4S)-4-[(3R)-4,4-difluoro-3-hydroxy-4-phenylbutyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]-, (5E)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 768400-09-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of prostaglandin analogs as EP4 receptor agonists for the treatment of glaucoma)
RN 768400-09-5 CAPLUS
CN 2H-1, 3-Oxazin-3(4H)-heptanoic acid, 4-[(1E)-4,4-difluoro-3-oxo-4-phenyl-1-buten-1-yl]dihydro-2-oxo-, 1-methylethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:459177 CAPLUS
DOCUMENT NUMBER: 113:59177
ORIGINAL REFERENCE NO.: 113:10015a, 10018a
TITLE: Preparation of oxazolidinone penetration enhancing compounds
INVENTOR(S): Rajadhyaksha, Vithal J.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 60 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9000407	A1	19900125	WO 1989-US2779	19890623
W: JP				
FR: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
US 4960771	A	19901002	US 1988-218316	19880712
EP 378657	A1	19900725	EP 1989-908033	19890623
EP 378657	B1	19940202		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 03500298	T	19910124	JP 1989-507546	19890623
JP 2901297	B2	19930607		
AT 101046	T	19940215	AT 1989-908033	19890623
			US 1988-218316	A 19880712
PRIORITY APPLN. INFO.:				
			EP 1989-908033	A 19890623
			WO 1989-US2779	W 19890623

OTHER SOURCE(S): CASREACT 113:59177; MARPAT 113:59177
GI




AB Title compds. I (R = H, C1-18 alkyl, cycloalkyl, aryl, aralkyl, alkoxy, etc.; X = O, R1N, R1 = H, alkyl, aralkyl, C1-18 acyl, cycloalkyl, etc.; Y = O, R2N, R2 = H, alkyl, aralkyl, cycloalkyl, C1-18 acyl, hydroxyalkyl, etc.; m = 2-4; n = 0-4, with several provisos) are prepared Me(CH2)9CHNH2CH2OH and ethylene carbonate were heated to .apprx.110° to give 4-decyloxazolidin-2-one (II). In a test using isosorbide dinitrate (0.07%) and 1.4% II, II showed superior permeation enhancing properties compared to control and a known permeation enhancer.


IT 128276-13-1 128276-14-2 128276-15-3

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RL: RCT (Reactant); RACT (Reactant or reagent)
(penetration enhancer for topical pharmaceuticals)


RN 128276-13-1 CAPLUS
CN 2H-1, 3-Oxazin-2-one, 4-dodecyltetrahydro- (CA INDEX NAME)



RN 128276-14-2 CAPLUS
CN 2H-1, 3-Oxazin-2-one, 4-dodecyltetrahydro-3-methyl- (CA INDEX NAME)



RN 128276-15-3 CAPLUS
CN 2H-1, 3-Oxazin-2-one, 3-acetyl-4-dodecyltetrahydro- (CA INDEX NAME)




L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:407421 CAPLUS
DOCUMENT NUMBER: 113:7421
ORIGINAL REFERENCE NO.: 113:1417a, 1420a
TITLE: Chemistry in adsorbed monolayers. 2. Thermal and photochemical grafting reactions at the polymer-filler interface

AUTHOR(S): McGarvey, Colette E.; Holden, David A.
CORPORATE SOURCE: Guelph-Waterloo Cent. Grad. Work Chem., Univ. Waterloo, Waterloo, ON, N2L 3G1, Can.
SOURCE: Langmuir (1990), 6(6), 1123-32
CODEN: LANGD5; ISSN: 0743-7463

DOCUMENT TYPE: Journal
LANGUAGE: English
AB The photochem. of adsorbed long-chain α -diazo ketones, azidoformates and α -azido ketones was examined as a method of coupling linear low-d. polyethylene with alumina, silica, and silica gel fillers. Photoreactions of monolayers adsorbed on alumina showed that grafting predominated and that interchain reactions were much less pronounced than analogous photoreactions in cyclohexane solution. Monofunctional coupling agents such as octadecanoyl azide provided no improvement in elongation at break, but bifunctional agents containing both a photochem. and a thermally active group, such as 12-azido-1-diazo-2-dodecanone and 1-diazo-11-dodecen-2-one, provided significant improvements. Evidence for improved adhesion between filler and polymer was provided by fracture-surface morphol. studies.

IT 126082-64-2P
RL: FORM (Formation, nonpreparative); PREP (Preparation)
(Formation of, in photolysis of nitrogen-containing coupling agents)

RN 126082-64-2 CAPLUS
CN 2H-1, 3-Oxazin-2-one, tetrahydro-4-(7-octenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1974:14882 CAPLUS
 DOCUMENT NUMBER: 80:14882
 ORIGINAL REFERENCE NO.: 80:2497a,2500a
 TITLE: Cyclization of azidoformates
 AUTHOR(S): Breslow, David S.; Ward, George A.
 CORPORATE SOURCE: Res. Cent., Hercules Inc., Wilmington, DE, USA
 SOURCE: Journal of Organic Chemistry (1973), 38(24), 4205-6
 CODEN: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The previously unidentified product (Breslow, D. S., et al., 1967) formed in the thermal decomposition of octadecyl azidoformate is 4-pentadecyltetrahydro-2H-1,3-oxazin-2-one. Thus, octadecyloxycarbonylnitrile "back-bites" to give both a five-membered and a six-membered ring compound. The compound reported previously as 4-methyltetrahydro-2H-1,3-oxazin-2-one is the 6-methyl derivative
 IT 42202-88-0P
 KL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 42202-88-0 CAPLUS
 CN 2H-1,3-Oxazin-2-one, tetrahydro-4-pentadecyl- (CA INDEX NAME)

